OBI-902 (TROP2 ADC)

OBI-902 is the next generation TROP2-directed ADC. OBI-902 is created by OBI’s proprietary platform GlycOBI™ and enzymatic technology EndoSymeOBI™. 

OBI-902 is currently at preclinical stage. Preliminary data of OBI-902 indicate that GlycOBI™ is an efficient platform to generate homogeneous ADCs with good stability and antitumor activity.